U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C6H9NO6
Molecular Weight 191.139
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ISOSORBIDE MONONITRATE

SMILES

C1[C@@]([H])([C@]2([H])[C@@]([H])([C@@]([H])(CO2)ON(=O)=O)O1)O

InChI

InChIKey=YWXYYJSYQOXTPL-SLPGGIOYSA-N
InChI=1S/C6H9NO6/c8-3-1-11-6-4(13-7(9)10)2-12-5(3)6/h3-6,8H,1-2H2/t3-,4+,5+,6+/m0/s1

HIDE SMILES / InChI
Isosorbide mononitrate (trade name Monoket), an organic nitrate, is a vasodilator with effects on both arteries and veins. It is used for the prevention of angina pectoris due to coronary artery disease and the treatment of acute and chronic angina pectoris, hypertension, and myocardial infarction. Isosorbide mononitrate is the major active metabolite of isosorbide dinitrate (ISDN), and most of the clinical activity of the dinitrate is attributable to the mononitrate. The principal pharmacological action of isosorbide mononitrate is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilation of the veins promotes peripheral pooling of blood and decreases venous return to the heart, thereby reducing left ventricular end-diastolic pressure and pulmonary capillary wedge pressure (preload). Arteriolar relaxation reduces systemic vascular resistance, systolic arterial pressure, and mean arterial pressure (afterload). Dilatation of the coronary arteries also occurs. The relative importance of preload reduction, afterload reduction and coronary dilatation remains undefined. Similar to other nitrites and organic nitrates, Isosorbide Mononitrate is converted to nitric oxide (NO), an active intermediate compound that activates the enzyme guanylate cyclase. Isosorbide mononitrate is rapidly and completely absorbed from the gastrointestinal tract. In humans, is not subject to first pass metabolism in the liver.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
MONOKET

Approved Use

monoket® is indicated for the prevention and treatment of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode.

Launch Date

7.4139841E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1151 ng/mL
120 mg 1 times / day steady-state, oral
dose: 120 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ISOSORBIDE MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
557 ng/mL
60 mg 1 times / day steady-state, oral
dose: 60 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ISOSORBIDE MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
388 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOSORBIDE MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
356 ng/mL
20 mg single, intravenous
dose: 20 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ISOSORBIDE MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
14241 ng × h/mL
120 mg 1 times / day steady-state, oral
dose: 120 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ISOSORBIDE MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6979 ng × h/mL
60 mg 1 times / day steady-state, oral
dose: 60 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ISOSORBIDE MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2524 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOSORBIDE MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
2647 ng × h/mL
20 mg single, intravenous
dose: 20 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ISOSORBIDE MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.2 h
120 mg 1 times / day steady-state, oral
dose: 120 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ISOSORBIDE MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
6.2 h
60 mg 1 times / day steady-state, oral
dose: 60 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ISOSORBIDE MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ISOSORBIDE MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4 h
20 mg single, intravenous
dose: 20 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ISOSORBIDE MONONITRATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
240 mg 1 times / day steady, oral
Highest studied dose
Dose: 240 mg, 1 times / day
Route: oral
Route: steady
Dose: 240 mg, 1 times / day
Sources:
unhealthy, adult
n = 312
Health Status: unhealthy
Condition: chronic stable angina pectoris
Age Group: adult
Sex: unknown
Population Size: 312
Sources:
Other AEs: Headache...
Other AEs:
Headache (57%)
Sources:
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
unhealthy, adult
n = 267
Health Status: unhealthy
Condition: chronic stable angina pectoris
Age Group: adult
Sex: unknown
Population Size: 267
Sources:
Disc. AE: Headache...
AEs leading to
discontinuation/dose reduction:
Headache (6 patients)
Sources:
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy, adult
n = 159
Health Status: unhealthy
Condition: myocardial infarction or congestive heart failure
Age Group: adult
Sex: unknown
Population Size: 159
Sources:
Disc. AE: Headache, Nausea...
AEs leading to
discontinuation/dose reduction:
Headache (5%)
Nausea (2%)
Sources:
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy, adult
n = 54
Health Status: unhealthy
Condition: myocardial infarction or congestive heart failure
Age Group: adult
Sex: unknown
Population Size: 54
Sources:
Disc. AE: Rash, Pruritus...
AEs leading to
discontinuation/dose reduction:
Rash (2%)
Pruritus (2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Headache 57%
240 mg 1 times / day steady, oral
Highest studied dose
Dose: 240 mg, 1 times / day
Route: oral
Route: steady
Dose: 240 mg, 1 times / day
Sources:
unhealthy, adult
n = 312
Health Status: unhealthy
Condition: chronic stable angina pectoris
Age Group: adult
Sex: unknown
Population Size: 312
Sources:
Headache 6 patients
Disc. AE
60 mg 1 times / day steady, oral
Recommended
Dose: 60 mg, 1 times / day
Route: oral
Route: steady
Dose: 60 mg, 1 times / day
Sources:
unhealthy, adult
n = 267
Health Status: unhealthy
Condition: chronic stable angina pectoris
Age Group: adult
Sex: unknown
Population Size: 267
Sources:
Nausea 2%
Disc. AE
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy, adult
n = 159
Health Status: unhealthy
Condition: myocardial infarction or congestive heart failure
Age Group: adult
Sex: unknown
Population Size: 159
Sources:
Headache 5%
Disc. AE
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy, adult
n = 159
Health Status: unhealthy
Condition: myocardial infarction or congestive heart failure
Age Group: adult
Sex: unknown
Population Size: 159
Sources:
Pruritus 2%
Disc. AE
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy, adult
n = 54
Health Status: unhealthy
Condition: myocardial infarction or congestive heart failure
Age Group: adult
Sex: unknown
Population Size: 54
Sources:
Rash 2%
Disc. AE
5 mg 1 times / day steady, oral
Dose: 5 mg, 1 times / day
Route: oral
Route: steady
Dose: 5 mg, 1 times / day
Sources:
unhealthy, adult
n = 54
Health Status: unhealthy
Condition: myocardial infarction or congestive heart failure
Age Group: adult
Sex: unknown
Population Size: 54
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
PubMed

PubMed

TitleDatePubMed
[Quality of life and angina pectoris. Comparison of the effects of 2 nitrate derivatives administered discontinuously: transdermal 10 mg nitroglycerine patch (12 hours) and long-acting oral 40 mg isosorbide-5-mononitrate (once a day)].
2001 Oct
[Antianginal and anti-ischemic effects of Mono Mac 50D preparation as an agent in combined treatment of patients with stable angina].
2002
[The influence of isosorbide mononitrate on skin blood flow in patients with Raynaud's syndrome].
2002
[Clinico-pharmacologic activity of organic nitrates].
2002 Apr-Jun
Power of experimental design studies for the validation of pharmaceutical processes: case study of a multilayer tablet manufacturing process.
2002 Aug
Combined therapy for secondary prophylaxis of variceal rebleeding?
2002 Aug
Randomized trial of isosorbide mononitrate versus misoprostol for cervical ripening at term.
2002 Aug
Pharmacologic efficacy in gastric variceal rebleeding and survival: including multivariate analysis.
2002 Aug
[Therapy of portal hypertension].
2002 Dec
"A La Carte" treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding.
2002 Dec
NCX-4016 (NO-aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo: role of nitric oxide.
2002 Dec 10
[Effect of isosorbide mononitrate on hypotensive action of enalapril in patients with mild and moderate hypertension].
2002 Jul
Pharmacological evaluation of a novel oxime derived from isosorbide-5-mononitrate on isolated rat superior mesenteric artery.
2002 Jul
[Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding].
2002 Jul
Direct injection of aqueous samples in packed column supercritical fluid chromatography of isosorbide-5-mononitrate from drug release testing.
2002 Jun 20
Efficacy of Terminalia arjuna in chronic stable angina: a double-blind, placebo-controlled, crossover study comparing Terminalia arjuna with isosorbide mononitrate.
2002 Mar-Apr
[Coronary artery disease observed in general hospitals: ETTIC study. Comparison between trimetazidine and mononitrate isosorbide for patients receiving betablockers].
2002 Nov
[How is antianginal therapy with pentaerythritol tetranitrate executed?].
2002 Nov 15
A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis.
2002 Oct
A validated high performance liquid chromatographic method for analysis of isosorbide mononitrate in bulk material and extended release formulations.
2002 Oct 15
Primary prophylaxis of variceal hemorrhage: a randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate.
2002 Sep
Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding.
2002 Sep
Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites.
2002 Sep
[The randomized controlled trial of isosorbide mononitrate plus propranolol compared with propranolol alone for the prevention of variceal rebleeding].
2002 Sep 10
Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis.
2002 Sep 9
Effects of 5-isosorbide mononitrate and propranolol on subclinical hepatic encephalopathy and renal function in patients with liver cirrhosis.
2002 Sep-Oct
[The impact of nitrates and mono-therapy and nitrates combined with angiotensin converting enzyme inhibitors on left ventricular remodeling and exercise capacity in patients after acute myocardial infarction].
2003
Band ligation versus propanolol and isosorbide mononitrate for primary prophylaxis of variceal bleeding.
2003 Aug
Aqueous humour flow after a single oral dose of isosorbide-5-mononitrate in healthy volunteers.
2003 Aug
Simultaneous determination of aspirin and isosorbide 5-mononitrate in formulation by reversed phase high pressure liquid chromatography.
2003 Aug 21
Intercommunity and temporal variation of eleven essential and five toxic elements in human placentas from deliveries in thirteen arctic and sub-arctic areas of Russia and Norway.
2003 Feb
Nitric oxide and squamous carcinoma.
2003 Feb
Effects of isosorbide mononitrate and AII inhibition on pulse wave reflection in hypertension.
2003 Feb
Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis.
2003 Feb
The critically ill liver patient: the variceal bleeder.
2003 Jan
Randomized, double-blind, placebo-controlled long-term study of isosorbide-5-mononitrate therapy in patients with left ventricular dysfunction after acute myocardial infarction.
2003 Jan
Serum profile of isosorbide mononitrate after vaginal administration in the third trimester.
2003 Jan
Comparative study of the use of diltiazem as an antispasmodic drug in coronary angiography via the transradial approach.
2003 Jul
Beneficial effects of angiotensin-converting enzyme inhibitor and nitrate association on left ventricular remodeling in patients with large acute myocardial infarction: the Delapril Remodeling after Acute Myocardial Infarction (DRAMI) trial.
2003 Jul
Optimal use of propranolol.
2003 Jun
"A la carte" treatment of portal hypertension or just "hors d'oeuvres".
2003 Jun
Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT.
2003 Jun
Amelioration of nitrate tolerance: matching strategies with mechanisms.
2003 Jun 4
Preserved endothelial function after long-term eccentric isosorbide mononitrate despite moderate nitrate tolerance.
2003 Jun 4
Severe portopulmonary hypertension in congenital hepatic fibrosis.
2003 Mar
Prevention of variceal rebleeding.
2003 Mar 15
Mercury content and speciation in the plankton and benthos of Lake Superior.
2003 Mar 20
Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle.
2003 Mar 7
Isosorbide-5-mononitrate treatment prevents cyclosporin A-induced platelet hyperactivation and the underlying nitric oxide-cyclic guanosine-3',5'-monophosphate disturbances.
2003 May 1
Effect of nitric oxide on exercise-induced proteinuria in rats.
2003 Nov
Patents

Sample Use Guides

The recommended regimen of monoket (isosorbide mononitrate) tablets, is 20 mg twice daily, with the doses seven hours apart. A starting dose of 5 mg (½ tablet of the 10 mg dosing strength) might be appropriate for persons of particularly small stature but should be increased to at least 10 mg by the second or third day of therapy. Dosage adjustments are not necessary for elderly patients or patients with altered hepatic or renal function.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment:: In vitro, an MTT assay demonstrated that Isosorbide mononitrate (ISMN) had a synergistic effect on the growth inhibitory effects of aspirin on HCT116 and SW620 colon cancer cells, while the growth of EA.hy926 normal endothelial cells was unaffected.
Unknown
Name Type Language
ISOSORBIDE MONONITRATE
INN   JAN   MART.   ORANGE BOOK   USAN   USP   VANDF   WHO-DD  
INN   USAN  
Official Name English
IS-5MN
Code English
ISOSORBIDE 5-MONONITRATE
Common Name English
BM 22.145
Code English
IS 5-MN
Code English
ISOSORBIDE MONONITRATE [MART.]
Common Name English
DILUTED ISOSORBIDE MONONITRATE
USP-RS  
Common Name English
ISOSORBIDE MONONITRATE [USP]
Common Name English
ISOSORBIDE DINITRATE ISOSORBIDE-5-MONONITRATE [MI]
Common Name English
ISOSORBIDE-5-MONONITRATE
Common Name English
MONOCORD
Brand Name English
MONOKET
Brand Name English
ISOSORBIDE MONONITRATE [JAN]
Common Name English
DILUTED ISOSORBIDE MONONITRATE [USP-RS]
Common Name English
BM 22.145IS 5-MNAHR-4698
Code English
ISMO
Brand Name English
ISOSORBIDE DINITRATE, DILUTED SPECIFIED IMPURITY C [EP]
Common Name English
ISOSORBIDE MONONITRATE [USAN]
Common Name English
ISOSORBIDE MONONITRATE [ORANGE BOOK]
Common Name English
ISOSORBIDE 5-NITRATE
Common Name English
IS-5-MN
Code English
ISOSORBIDE MONONITRATE [WHO-DD]
Common Name English
BM-22.145
Code English
ISOSORBIDE MONONITRATE [VANDF]
Common Name English
BM-22-145
Code English
ISO-5-MONONITRATE
Common Name English
BM-22145
Code English
AHR-4698
Code English
ISMN
Common Name English
D-GLUCITOL, 1,4:3,6-DIANHYDRO-, 5-NITRATE
Systematic Name English
DILUTED ISOSORBIDE MONONITRATE [USP MONOGRAPH]
Common Name English
CORANGIN
Brand Name English
NSC-758619
Code English
ISOSORBIDE MONONITRATE [INN]
Common Name English
IMDUR
Brand Name English
Classification Tree Code System Code
NDF-RT N0000009909
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
NDF-RT N0000007647
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
WHO-ATC C01DA14
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
NCI_THESAURUS C29707
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
NDF-RT N0000007647
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
NDF-RT N0000175415
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
NDF-RT N0000007647
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
NDF-RT N0000007647
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
WHO-VATC QC01DA14
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
Code System Code Type Description
ECHA (EC/EINECS)
240-197-2
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
PRIMARY
RXCUI
28004
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
PRIMARY RxNorm
INN
5177
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
PRIMARY
MERCK INDEX
M6541
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
PRIMARY Merck Index
EVMPD
SUB08336MIG
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
PRIMARY
FDA UNII
LX1OH63030
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
PRIMARY
MESH
C030397
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
PRIMARY
USP_CATALOG
1353102
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
PRIMARY USP-RS
EVMPD
SUB30087
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
PRIMARY
PUBCHEM
27661
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
PRIMARY
NCI_THESAURUS
C47575
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
PRIMARY
DRUG BANK
DB01020
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
PRIMARY
DRUG CENTRAL
1506
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
PRIMARY
WIKIPEDIA
ISOSORBIDE MONONITRATE
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
PRIMARY
EPA CompTox
16051-77-7
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
PRIMARY
CAS
16051-77-7
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
PRIMARY
EVMPD
SUB12087MIG
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
ALTERNATIVE
ChEMBL
CHEMBL1311
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
PRIMARY
IUPHAR
7052
Created by admin on Fri Jun 25 22:11:57 UTC 2021 , Edited by admin on Fri Jun 25 22:11:57 UTC 2021
PRIMARY